SPECIAL IMMUNE SIGNATURE OF MM PATIENTS IN LONG TERM COMPLETE RESPONSE (LTCR) WITH NEGATIVE MINIMAL RESIDUAL DISEASE (MRD) AFTER AUTOLOGOUS TRANSPLANT (ASCT): A SINGLE CENTRE EXPERIENCE
(Abstract release date: 05/19/16)
EHA Library. Aguado Bueno B. 06/09/16; 132871; E1322
Dr. Beatriz Aguado Bueno
Contributions
Contributions
Abstract
Abstract: E1322
Type: Eposter Presentation
Background
The immune profile in MM patients in long term complete remission (LTCR) could be relevant in MM control and minimal residual disease (MRD) monitoring.
Aims
To evaluate this hypothesis, we have analyzed the immune profile and the MRD status of a group of LTCR-MM patients after autologous transplant (ASCT) and we have compared the results with a healthy control group.
Methods
13 MM patients, median 60 y (46-71) in LTCR for > 7 years, median 9 y (7-19) after ASCT were included. Only 2 patients had received thalidomide as induction. The rest only chemotherapy schemes. No other patient had received new drugs neither maintenance. 7 patients received conditioning with HD Melphalan and 6 with Busulphan + Melphalan. Only 2 patient showed high hisk iFISH, one with del(17p) and other with t(4;14). Control arm included 15 age-matched healthy blood donors (HD). Peripheral blood was immunophenotyped by multiparametric flow cytometry with 8 colours and CD4+ and CD8+ T-cells, B lymphocytes and NK cells were quantified. Serum immunoglobulins, free light chains and heavy/light chains (HLC) were quantified. MRD was evaluate with bone marrow multiparametric cytometry study (8 colours). Response was evaluated by IMWG Criteria.
Results
The percentage of CD4+ T-cells in the LTCR group was significantly lower than in HD (p=0.0002), whereas no differences were observed in the proportion of total CD8+ T-cells (p=0.3046). Conversely, the relative values of NK-cells (CD3-CD56+CD16+) were increased in the LTCR group (p=0,0514). The percentage of total B-cells (CD19+CD20+) in the patients was within normal range and no significant differences were found when compared to HD. Remarkably, the normalization of HLC measurements confirmed a complete reconstitution of the immune paresis in these patients, and a negative MRD by multiparametric flow cytometry ratified its usefulness at demonstrating a sustained complete response.
Conclusion
LTCR-MM MRD neg patients could express a particular immune signature which could reflect a “high quality” immune reconstitution in terms of anti-tumor immunological surveillance and the recovery of the humoral immunity. More studies are needed to confirm these results, with patients treated with new drugs combinations including immunomodulatory ones.
Session topic: E-poster
Keyword(s): Immune reconstitution
Type: Eposter Presentation
Background
The immune profile in MM patients in long term complete remission (LTCR) could be relevant in MM control and minimal residual disease (MRD) monitoring.
Aims
To evaluate this hypothesis, we have analyzed the immune profile and the MRD status of a group of LTCR-MM patients after autologous transplant (ASCT) and we have compared the results with a healthy control group.
Methods
13 MM patients, median 60 y (46-71) in LTCR for > 7 years, median 9 y (7-19) after ASCT were included. Only 2 patients had received thalidomide as induction. The rest only chemotherapy schemes. No other patient had received new drugs neither maintenance. 7 patients received conditioning with HD Melphalan and 6 with Busulphan + Melphalan. Only 2 patient showed high hisk iFISH, one with del(17p) and other with t(4;14). Control arm included 15 age-matched healthy blood donors (HD). Peripheral blood was immunophenotyped by multiparametric flow cytometry with 8 colours and CD4+ and CD8+ T-cells, B lymphocytes and NK cells were quantified. Serum immunoglobulins, free light chains and heavy/light chains (HLC) were quantified. MRD was evaluate with bone marrow multiparametric cytometry study (8 colours). Response was evaluated by IMWG Criteria.
Results
The percentage of CD4+ T-cells in the LTCR group was significantly lower than in HD (p=0.0002), whereas no differences were observed in the proportion of total CD8+ T-cells (p=0.3046). Conversely, the relative values of NK-cells (CD3-CD56+CD16+) were increased in the LTCR group (p=0,0514). The percentage of total B-cells (CD19+CD20+) in the patients was within normal range and no significant differences were found when compared to HD. Remarkably, the normalization of HLC measurements confirmed a complete reconstitution of the immune paresis in these patients, and a negative MRD by multiparametric flow cytometry ratified its usefulness at demonstrating a sustained complete response.
Conclusion
LTCR-MM MRD neg patients could express a particular immune signature which could reflect a “high quality” immune reconstitution in terms of anti-tumor immunological surveillance and the recovery of the humoral immunity. More studies are needed to confirm these results, with patients treated with new drugs combinations including immunomodulatory ones.
Session topic: E-poster
Keyword(s): Immune reconstitution
Abstract: E1322
Type: Eposter Presentation
Background
The immune profile in MM patients in long term complete remission (LTCR) could be relevant in MM control and minimal residual disease (MRD) monitoring.
Aims
To evaluate this hypothesis, we have analyzed the immune profile and the MRD status of a group of LTCR-MM patients after autologous transplant (ASCT) and we have compared the results with a healthy control group.
Methods
13 MM patients, median 60 y (46-71) in LTCR for > 7 years, median 9 y (7-19) after ASCT were included. Only 2 patients had received thalidomide as induction. The rest only chemotherapy schemes. No other patient had received new drugs neither maintenance. 7 patients received conditioning with HD Melphalan and 6 with Busulphan + Melphalan. Only 2 patient showed high hisk iFISH, one with del(17p) and other with t(4;14). Control arm included 15 age-matched healthy blood donors (HD). Peripheral blood was immunophenotyped by multiparametric flow cytometry with 8 colours and CD4+ and CD8+ T-cells, B lymphocytes and NK cells were quantified. Serum immunoglobulins, free light chains and heavy/light chains (HLC) were quantified. MRD was evaluate with bone marrow multiparametric cytometry study (8 colours). Response was evaluated by IMWG Criteria.
Results
The percentage of CD4+ T-cells in the LTCR group was significantly lower than in HD (p=0.0002), whereas no differences were observed in the proportion of total CD8+ T-cells (p=0.3046). Conversely, the relative values of NK-cells (CD3-CD56+CD16+) were increased in the LTCR group (p=0,0514). The percentage of total B-cells (CD19+CD20+) in the patients was within normal range and no significant differences were found when compared to HD. Remarkably, the normalization of HLC measurements confirmed a complete reconstitution of the immune paresis in these patients, and a negative MRD by multiparametric flow cytometry ratified its usefulness at demonstrating a sustained complete response.
Conclusion
LTCR-MM MRD neg patients could express a particular immune signature which could reflect a “high quality” immune reconstitution in terms of anti-tumor immunological surveillance and the recovery of the humoral immunity. More studies are needed to confirm these results, with patients treated with new drugs combinations including immunomodulatory ones.
Session topic: E-poster
Keyword(s): Immune reconstitution
Type: Eposter Presentation
Background
The immune profile in MM patients in long term complete remission (LTCR) could be relevant in MM control and minimal residual disease (MRD) monitoring.
Aims
To evaluate this hypothesis, we have analyzed the immune profile and the MRD status of a group of LTCR-MM patients after autologous transplant (ASCT) and we have compared the results with a healthy control group.
Methods
13 MM patients, median 60 y (46-71) in LTCR for > 7 years, median 9 y (7-19) after ASCT were included. Only 2 patients had received thalidomide as induction. The rest only chemotherapy schemes. No other patient had received new drugs neither maintenance. 7 patients received conditioning with HD Melphalan and 6 with Busulphan + Melphalan. Only 2 patient showed high hisk iFISH, one with del(17p) and other with t(4;14). Control arm included 15 age-matched healthy blood donors (HD). Peripheral blood was immunophenotyped by multiparametric flow cytometry with 8 colours and CD4+ and CD8+ T-cells, B lymphocytes and NK cells were quantified. Serum immunoglobulins, free light chains and heavy/light chains (HLC) were quantified. MRD was evaluate with bone marrow multiparametric cytometry study (8 colours). Response was evaluated by IMWG Criteria.
Results
The percentage of CD4+ T-cells in the LTCR group was significantly lower than in HD (p=0.0002), whereas no differences were observed in the proportion of total CD8+ T-cells (p=0.3046). Conversely, the relative values of NK-cells (CD3-CD56+CD16+) were increased in the LTCR group (p=0,0514). The percentage of total B-cells (CD19+CD20+) in the patients was within normal range and no significant differences were found when compared to HD. Remarkably, the normalization of HLC measurements confirmed a complete reconstitution of the immune paresis in these patients, and a negative MRD by multiparametric flow cytometry ratified its usefulness at demonstrating a sustained complete response.
Conclusion
LTCR-MM MRD neg patients could express a particular immune signature which could reflect a “high quality” immune reconstitution in terms of anti-tumor immunological surveillance and the recovery of the humoral immunity. More studies are needed to confirm these results, with patients treated with new drugs combinations including immunomodulatory ones.
Session topic: E-poster
Keyword(s): Immune reconstitution
{{ help_message }}
{{filter}}